Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 01
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Neurocrine Biosciences Inc
NBIX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$141.84
3.49
2.52%
Dern. MÀJ: Sep 30, 4:48 PM
$141.00
2.65
1.92%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Neurocrine Biosciences Financials
Neurocrine Biosciences (NBIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share
Benzinga Newsdesk
PRO
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance
Neurocrine shares fell 8% after mixed earnings, strong Ingrezza sales, and a 2026 outlook that met expectations. Analysts see long-term upside despite short-term pressure.
Vandana Singh
Neurocrine Biosciences Q4 Earnings Assessment
Benzinga Insights
PRO
Neurocrine Biosciences Expects FY26 INGREZZA Net Product Sales Of $2.70B-$2.80B
Full-Year 2026 Financial Guidance Range(in millions)Low HighINGREZZA Net Product Sales 1$ 2,700 $
Benzinga Newsdesk
